This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Qingcong Lin, PhD
Chief Executive Officer at Biocytogen Boston Corp.

Profile

Dr. Qingcong Lin is SVP of Biocytogen and CEO of Biocytogen Boston Corporation. Prior to joining Biocytogen, Dr. Lin was SVP of Shenogen Pharma Group. Dr. Lin has extensive expertise in multiple therapeutic areas, including cancer, CVMD, neurology, immunology & inflammation and various technologies, including genetically engineered mouse models, therapeutic antibody engineering, affinity maturation and optimization. Prior to joining Sheongen, Dr. Lin worked at Pfizer as a principal research scientist II and group leader of antibody engineering group. Before joining Pfizer, he worked at Wyeth and Harvard Medical School as Director of Gene Modification Lab of Harvard-Partners Center for Genetics and Genomics. Dr. Lin received Ph.D. from Albert-Einstein College of Medicine and completed his postdoctoral training at Harvard Medical School.


Meet Dr Lin

Agenda Sessions

  • Accelerating Therapeutic Antibody Discovery with Three Distinct Humanized Mouse Models

    On Demand
  • Accelerating Therapeutic Antibody Discovery with Three Distinct Humanized Mouse Models

    On Demand
  • SCIENTIFIC BRIEFING: Accelerating Therapeutic Antibody Discovery with Three Distinct Humanized Mouse Models

    13:45